鉅子生物(02367.HK)午後倒升逾3% 控股股東擬3至6個月內斥最少2億元增持
鉅子生物(02367.HK)控股股東擬3至6個月內斥最少2億元增持股份。該行今早(9日)最低見56.2元,考驗近250移動平均線支持,下午獲消息刺激倒升,現報60.95元,升3.31%,成交1,755.5萬股,涉資10.18億元。
鉅子生物中午公佈,接獲控股股東Juzi Holding通知,基於對公司價值的認可和對未來整體業務發展及增長潛力的信心,Juzi Holding計劃自本公告日期起三至六個月內增持公司股份,增持金額不低於2億元。 目前Juzi Holding持有公司合共5.81億股股份,佔已發行股份約54.26%。倘增持計劃實施,公司仍將維持已發行股份的足夠公衆持股量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.